Hormone sensitive locally advanced prostate cancer, Hormone sensitive metastatic prostate cancer
Adult: As triptorelin embonate 3.75 mg depot preparation: 3.75 mg once every 4 weeks. As triptorelin embonate 11.25 mg depot preparation: 11.25 mg once every 12 weeks. All doses are given via IM inj.
Intramuscular
Locally advanced prostate cancer
Adult: Alternative to surgical castration; adjuvant treatment to radiotherapy in patients with high-risk cases; neoadjuvant treatment before radiotherapy in patients with high-risk cases; adjuvant treatment to radical prostatectomy in patients with cases at high risk of disease progression: As triptorelin acetate 3 mg sustained-release depot preparation: 3 mg once every 4 weeks. As triptorelin pamoate 11.25 mg sustained-release depot preparation: 11.25 mg once every 12 weeks. As triptorelin pamoate 22.5 mg sustained-release depot preparation: 22.5 mg every 24 weeks. All doses are given via IM inj.
Intramuscular
Adjuvant treatment of hormone-responsive early stage breast cancer in premenopausal women
Adult: In combination with tamoxifen or an aromatase inhibitor in patients at high risk of recurrence: As triptorelin acetate 3 mg sustained-release depot preparation: 3 mg every 4 weeks given via deep IM inj. Initiate treatment at least 6-8 weeks (equivalent to at least 2 doses) before starting the aromatase inhibitor. Thereafter, do not interrupt triptorelin treatment to avoid rebound increases in estrogen levels. Recommended treatment duration: 5 years.
Intramuscular
Endometriosis
Adult: As triptorelin acetate 3 mg sustained-release depot preparation: 3 mg once every 4 weeks. As triptorelin pamoate 11.25 mg sustained-release depot preparation: 11.25 mg every 3 months. Initiate treatment during the 1st 5 days of the menstrual cycle. Max treatment duration: 6 months. All doses are given via IM inj.
Intramuscular
Central precocious puberty
Child: As triptorelin pamoate 11.25 mg sustained-release depot preparation: Onset in girls before 8 years; in boys before 10 years 11.25 mg every 3 months. As triptorelin embonate 22.5 mg depot preparation: ≥2 years with onset in girls before 8 years; in boys before 10 years 22.5 mg once every 24 weeks. Discontinue treatment around the physiological age of puberty in girls and boys, and in girls with bone maturation of >12 years. All doses are given via IM inj.
Intramuscular
Metastatic prostate cancer
Adult: As triptorelin acetate 3 mg sustained-release depot preparation: 3 mg once every 4 weeks. As triptorelin pamoate 11.25 mg sustained-release depot preparation: 11.25 mg once every 12 weeks. As triptorelin pamoate 22.5 mg sustained-release depot preparation: 22.5 mg every 24 weeks. All doses are given via IM inj. Continue treatment upon the development of castrate-resistant prostate cancer (refer to local treatment guidelines).
Intramuscular
Palliative treatment of advanced prostate cancer
Adult: As triptorelin pamoate 3.75 mg depot preparation: 3.75 mg every 4 weeks via IM inj into the buttock.
Intramuscular
Uterine fibroids
Adult: Treatment of cases prior to surgery or when surgery is inappropriate: As triptorelin acetate 3 mg sustained-release depot preparation: 3 mg once every 4 weeks given via deep IM inj for at least 3 months. Initiate treatment during the 1st 5 days of the menstrual cycle. Max treatment duration: 6 months.
Intramuscular
Libido in severe hypersexuality or sexual deviation
Adult: For the reduction of sex drive in men with severe sexual deviations: In combination with psychotherapy: As triptorelin embonate prolonged-release depot preparation: 11.25 mg every 12 weeks. Consider the addition of anti-androgen when initiating therapy to counteract transient rise in serum testosterone levels, and when stopping the treatment due to increased risk of sensitivity to restored testosterone.
Parenteral
Hormone sensitive locally advanced prostate cancer, Hormone sensitive metastatic prostate cancer
Adult: As triptorelin acetate 3.75 mg prolonged-release depot preparation: 3.75 mg once every 4 weeks given via deep IM or SC inj. Alternatively in some countries, the treatment regimen may initially use 0.1 mg once daily (triptorelin acetate 0.1 mg immediate-release preparation) given via SC inj for 7 days; followed by 3.75 mg on day 8 (triptorelin acetate 3.75 mg prolonged-release depot preparation) given via IM inj, repeated every 4 weeks. Dosage administration may vary among individual product formulation and between countries (refer to specific product guideline).
Parenteral
Endometriosis, Uterine fibroids
Adult: As triptorelin acetate 3.75 mg prolonged-release depot preparation: 3.75 mg once every 4 weeks given via deep IM or SC inj. Initiate treatment during the 1st 5 days of the menstrual cycle. Max treatment duration: 6 months (for endometriosis); 3 or 6 months (for uterine fibroids). Dosage administration may vary among individual product formulation and between countries (refer to specific product guideline).
Parenteral
Central precocious puberty
Child: As triptorelin acetate 3.75 mg prolonged-release depot preparation: Onset in girls before 9 years; in boys before 10 years <20 kg: 1.875 mg; 20-30 kg: 2.5 mg; >30 kg: 3.75 mg. Give the 1st 3 doses on days 0, 14, and 28 via IM or SC inj. Thereafter, further doses are administered once every 4 weeks, then may be increased to once every 3 weeks if necessary. Discontinue treatment if a bone maturation of >12 years in girls or >13 years in boys is achieved.